Get the Stockscreener App
1.45
3.57%
0.05
After Hours:
1.42
-0.03
-2.07%
Marker Therapeutics Inc stock is traded at $1.45, with a volume of 64,088.
It is up +3.57% in the last 24 hours and up +3.57% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
See More
Previous Close:
$1.40
Open:
$1.41
24h Volume:
64,088
Relative Volume:
0.56
Market Cap:
$24.18M
Revenue:
$3.55M
Net Income/Loss:
$-12.16M
P/E Ratio:
-1.5943
EPS:
-0.9095
Net Cash Flow:
$-12.01M
1W Performance:
+4.32%
1M Performance:
+3.57%
6M Performance:
+18.85%
1Y Performance:
+27.19%
1-Day Range:
$1.41
$1.46
1-Week Range:
$1.38
$1.4694
52-Week Range:
$0.8099
$4.07
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.45 | 23.34M | 3.55M | -12.16M | -12.01M | -0.9095 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Marker Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline ProgressesMargin Compression Risk - Newser
Marker Therapeutics Inc. (MRKR) Q1 2026 Earnings: EPS Beat Expectations Amid Development Stage OperationsRevenue Estimate Trend - Newser
Marker Therapeutics Q1 2026 Earnings: Loss Narrows as Clinical Progress ContinuesPost-Earnings Drift - Newser
Marker Therapeutics (MRKR) upgraded to buy: What does it mean for the stock? - MSN
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern - Stock Titan
Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) — 10-Q Summary - TradingView
MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027 - TradingView
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Marker Therapeutics (MRKR) Fell -0.82% — Is a Recovery Ahead? 2026-05-15Community Pattern Alerts - Newser
Marker Therapeutics (MRKR) Q4 2025 Earnings: $-0.09 EPS Surges Past $-0.20 EstimatesNew Analyst Coverage - Newser
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer - The Manila Times
TradingKey - TradingKey
Marker Therapeutics MRKR Q4 2025 loss narrows unexpectedly, beating estimates by 55%; shares tick higher.Crowd Entry Points - Newser
Number of shareholders of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
MSN Money - MSN
Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates - MSN
Marker Therapeutics (NASDAQ: MRKR) holders back share increase but reject voting change - Stock Titan
Pancreatic Cancer Pipeline Enters a New Era of Precision - openPR.com
Is Marker Therapeutics (MRKR) stock moving unpredictably (Ticks Down) 2026-04-24Safe Entry Stocks - newser.com
Is Marker Therapeutics (MRKR) stock worth buying today | Q4 2025: EPS Exceeds ExpectationsFinancial Data - Cổng thông tin điện tử tỉnh Lào Cai
Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02 - MSN
Stock List: Research Stocks from Around the World - GuruFocus
Ideas Watch: What are Marker Therapeutics Incs growth levers2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-04-06 22:29:12 - baoquankhu1.vn
Can Marker Therapeutics (MRKR) Stock Rebound in 2026 | Price at $1.44, Up 9.09%Expert Insights - Newser
Total debt per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
EBITDA per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
Marker Therapeutics, Inc. (MRKR) stock price, news, quote and history - Yahoo Finance UK
EPS Watch: What is the long term forecast for Marker Therapeutics Inc stock2026 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Marker Therapeutics (MRKR) Stock Leading the Market | Price at $1.77, Up 1.14%Resistance Breakout Stocks - Newser
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
MRKR SEC FilingsMarker Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Sell: Can Marker Therapeutics Inc deliver consistent dividends2026 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exit Recap: Should I hold or sell Marker Therapeutics Inc now2026 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday - Defense World
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
Q2 Earnings Estimate for MRKR Issued By Brookline Cap M - Defense World
Form DEF 14A Marker Therapeutics For: 20 March - Investing.com
Marker Therapeutics (NASDAQ: MRKR) proxy eyes 130M shares, lower vote hurdle - Stock Titan
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
[ARS] Marker Therapeutics, Inc. SEC Filing - Stock Titan
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones - TipRanks
Marker Therapeutics, Inc. 2025 10-K: Clinical-Stage Immuno-Oncology Pipeline, Regulatory Strategy, and Competitive Landscape Overview - Minichart
MARKER THERAPEUTICS, INC. (MRKR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Marker Therapeutics (MRKR) outlines MAR-T cancer pipeline, MT-601 trials and grant funding - Stock Titan
Marker Therapeutics 10-K: Revenue $3.55M; Net loss $12.18M - TradingView
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):